Quest Diagnostics has integrated its Haystack MRD test and comprehensive genomic profiling services into Flatiron Health’s OncoEMR platform, giving community oncology providers streamlined access to molecular testing within their existing clinical workflows.

The integration is launching through a pilot programme with American Oncology Network (AON) and other community oncology providers. Quest said it plans to expand access during the second half of the year to around 4,700 clinicians across Flatiron’s network of approximately 1,600 community-based cancer care locations in the US.

The company said it is the largest clinical reference laboratory to make oncology tests available through the opt-in OncoEMR Molecular Profiling Integration (MPI) feature, which is designed to simplify the ordering and reporting of complex molecular diagnostic tests.

Molecular oncology testing often analyses large numbers of genetic biomarkers to identify tumour characteristics that may help guide treatment decisions. Integrating these tests directly into electronic health records aims to reduce administrative steps by allowing clinicians to order tests and receive results without leaving their normal workflow.

Under the pilot programme, participating providers can order Quest’s Haystack MRD circulating tumour DNA (ctDNA) test for solid tumour cancers alongside the company’s comprehensive genomic profiling portfolio. The genomic profiling panels analyse up to 530 genes associated with therapy response to support treatment planning.

Nearly 200 AON sites are now able to access the integration. Quest said the wider rollout will extend availability to thousands more clinicians using the Flatiron network.

Quincy Weatherspoon, chief network officer, US point of care at Flatiron Health, said: “By integrating Quest’s advanced oncology services directly into existing workflows, we’re making it easier for physicians to access critical testing insights without adding complexity to their day.”

The integration forms part of a wider move across oncology to embed advanced molecular diagnostics within electronic health record systems, helping clinicians access genomic information more efficiently as precision medicine becomes increasingly established in routine cancer care.

The announcement follows another milestone for Quest’s Haystack MRD test after it recently received approval from New York State’s Clinical Laboratory Evaluation Program. The approval means the test can now be offered across all 50 US states, extending access to one of the country’s most closely regulated laboratory markets.

Minimal residual disease testing detects small amounts of circulating tumour DNA that may remain after treatment and can help identify evidence of disease recurrence before it becomes clinically apparent. Meanwhile, comprehensive genomic profiling identifies genetic alterations that may influence treatment selection, making both technologies increasingly important components of personalised cancer care.

Quest said it expects to make the OncoEMR MPI integration available more broadly across the Flatiron network later this year.